Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders
Open Access
- 2 December 2015
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 76 (1) , 1-12
Abstract
Cardiovascular and metabolic disorders, such as hypertension, insulin resistance, dyslipidemia or obesity are linked with chronic low-grade inflammation and dysregulation of the renin–angiotensin system (RAS). Consequently, RAS inhibition by ACE inhibitors or angiotensin AT1 receptor (AT1R) blockers is the evidence-based standard for cardiovascular risk reduction in high-risk patients, including diabetics with albuminuria. In addition, RAS inhibition reduces the new onset of diabetes mellitus. Yet, the high and increasing prevalence of metabolic disorders, and the high residual risk even in properly treated patients, calls for additional means of pharmacological intervention. In the past decade, the stimulation of the angiotensin AT2 receptor (AT2R) has been shown to reduce inflammation, improve cardiac and vascular remodeling, enhance insulin sensitivity and increase adiponectin production. Therefore, a concept of dual AT1R/AT2R modulation emerges as a putative means for risk reduction in cardio-metabolic diseases. The approach employing simultaneous RAS blockade (AT1R) and RAS stimulation (AT2R) is distinct from previous attempts of double intervention in the RAS by dual blockade. Dual blockade abolishes the AT1R-linked RAS almost completely with subsequent risk of hypotension and hypotension-related events, i.e. syncope or renal dysfunction. Such complications might be especially prominent in patients with renal impairment or patients with isolated systolic hypertension and normal-to-low diastolic blood pressure values. In contrast to dual RAS blockade, the add-on of AT2R stimulation does not exert significant blood pressure effects, but it may complement and enhance the anti-inflammatory and antifibrotic/de-stiffening effects of the AT1R blockade and improve the metabolic profile. Further studies will have to investigate these putative effects in particular for settings in which blood pressure reduction is not primarily desired.Keywords
Funding Information
- Scientific Grant Agency VEGA (VEGA 1-0380-14)
- Agency for Science and Research Support APVV (APVV 0205-11 0205-11)
- Vicore Pharma (Short term student fellowship)
- Vicore Phamra (Free drug supplied of Compound21)
This publication has 115 references indexed in Scilit:
- European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)European Heart Journal, 2012
- Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesityAmerican Journal of Physiology-Renal Physiology, 2011
- Role of the angiotensin II AT2 receptor in inflammation and oxidative stress: opposing effects in lean and obese Zucker ratsAmerican Journal of Physiology-Renal Physiology, 2011
- Adipokines in inflammation and metabolic diseaseNature Reviews Immunology, 2011
- Macrophages, Inflammation, and Insulin ResistanceAnnual Review of Physiology, 2010
- Epoxyeicosatrienoic Acid Agonist Rescues the Metabolic Syndrome Phenotype of HO-2-Null MiceThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parametersNature Medicine, 2009
- Transcriptional Integration of TLR2 and TLR4 Signaling at the NCoR Derepression CheckpointMolecular Cell, 2009
- Alternative M2 Activation of Kupffer Cells by PPARδ Ameliorates Obesity-Induced Insulin ResistanceCell Metabolism, 2008
- Inflammation and metabolic disordersNature, 2006